ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret...
https://pubmed.ncbi.nlm.nih.gov/39261676/Actively Recruiting
Led by Ichnos Sciences SA · Updated on 2026-04-01
200
Participants Needed
32
Research Sites
N/A
Total Duration
Researchers are evaluating ISB 2001 in adults with relapsed or refractory multiple myeloma RR MM who have already been treated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 therapies but remain resistant or intolerant to these treatments. This first-in-human, Phase 1, open-label study aims to assess the safety and anti-myeloma activity of ISB 2001. The study is sponsored by Ichnos Sciences SA and involves participants who have measurable disease and adequate organ function. The study has two parts dose escalation and dose expansion. In the dose escalation phase, participants receive increasing doses of ISB 2001 to determine the maximum safe dose. In the dose expansion phase, participants receive ISB 2001 at the optimal dose identified to further confirm safety and biological activity. ISB 2001 is given weekly on Days 1, 8, 15, and 22 of each 28-day cycle, with an additional step-up dose on Day 4 of Cycle 1. Treatment continues until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular monitoring for treatment-emergent adverse events and dose-limiting toxicities during the first cycle, with follow-up visits extending up to 18 months. Researchers will measure drug levels in the blood, immune responses to the drug, and multiple clinical outcomes related to disease response and progression. Ongoing assessments will include physical exams, performance status, and laboratory tests to track safety and treatment effects throughout the study period.
CONDITIONS
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
I
Ichnos Sciences Clinical Trials Administrator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ichnos Sciences SA
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ISB 2001 (investigational, TRIgnite-1 study) | Standard Therapies (per guidelines) |
|---|---|---|
| What it is | TRIgnite-1 is a first-in-human, open-label clinical trial testing ISB 2001, a trispecific T cell engager antibody, administered as escalating and expansion doses in adults with relapsed or refractory multiple myeloma. | Current standard therapies for relapsed/refractory multiple myeloma after two or more lines of prior treatment include combinations such as daratumumab (an anti-CD38 antibody), carfilzomib or elotuzumab with lenalidomide and dexamethasone, as recommended in international guidelines. |
| Role in trial | ISB 2001 is tested as an experimental therapy to determine safety, tolerability, and initial evidence of activity in a population with prior multiple myeloma treatments. | Standard regimens are used in clinical practice to control disease in patients whose myeloma has relapsed or become refractory to previous treatments. |
| Primary use | Being evaluated for the treatment of relapsed or refractory multiple myeloma in adults who have previously received and failed standard therapies. | Recommended as established treatment choices to manage relapsed or refractory multiple myeloma and support prolonged disease control. |
| How it is given or performed | ISB 2001 is administered as a parenteral (injection) therapy in dose-escalation cohorts and later at the selected regimen in dose expansion; dosing details follow a regimen determined by safety monitoring. | Standard therapies are usually given as intravenous infusions or oral agents, depending on the drugs used; treatment schedules follow established guideline dosing for each regimen. |
| Evidence status | Evidence for ISB 2001 in humans is limited to early-phase clinical investigation and preclinical studies; published clinical outcomes in relapsed/refractory multiple myeloma are not yet available. | Extensive clinical evidence supports standard regimens, which have demonstrated improved response rates, progression-free survival, and overall survival in multiple randomized studies over the last decade. |
| Important limitations | As a first-in-human, early-phase study, ISB 2001 has not yet established clinical efficacy, long-term safety, or comparative effectiveness. The regimen and dosing are still being refined. | Standard therapies may be limited by previous exposure, cumulative toxicity (such as neuropathy or cytopenias), and resistance. Multiple relapses often reduce response durability in this heavily pretreated population. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Repeated 28-day cycles until disease progression or discontinuation
Participants receive ISB 2001 by injection weekly on Days 1, 8, 15, and 22 of each 28-day cycle, with an additional step-up dose on Day 4 of Cycle 1. Treatment continues until disease progression, unacceptable toxicity, stopping criteria, or participant withdrawal.
Weekly visits for each 28-day cycle
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret...
https://pubmed.ncbi.nlm.nih.gov/39261676/Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova...
https://pubmed.ncbi.nlm.nih.gov/42206665/Ichnos Sciences SA
Lead Sponsor